Prostate‐specific membrane antigen expression in melanoma metastases
- 11 June 2020
- journal article
- research article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 47 (12) , 1115-1122
Abstract
Background: Prostate‐specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga‐PSMA‐11) for prostate cancer staging. PSMA‐PET/CT (positron emission tomography/computed tomography) performed for prostate cancer has been observed to detect melanoma metastases. The aim of this study was to investigate the performance of PSMA immunohistochemistry on resected melanoma metastases to explore its use as a diagnostic imaging biomarker for melanoma.Methods: A total of 41 specimens with stage III/IV melanoma were stained with PSMA immunohistochemistry. All specimens required both disease and control regions. Two pathologists scored the specimens and a receiver operating characteristic (ROC) curve was plotted. Western blot and multiplex immunofluorescence were also performed.Results: The area under the ROC curve was 0.82, suggesting that PSMA has excellent discriminatory power in melanoma metastases. Sensitivity is 82.9% and specificity 73.2%. Immunohistochemistry and Western blot reveal that PSMA staining in melanoma consistently and most intensely occurs in tumor neovasculature. Multiplex immunofluorescence shows that melanocytes may also weakly express PSMA.Conclusion: The performance of PSMA immunohistochemistry in melanoma metastases contrasts with that reported in prostate cancer studies. This study indicates that PSMA shows promise for use as a novel biomarker in melanoma and justifies further research in the clinical setting with potential as a PET/CT radiotracer and intraoperative fluorescence marker for melanoma.Keywords
This publication has 33 references indexed in Scilit:
- 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Focus, 2018
- Incidental Metastatic Melanoma Identified on 68Ga–Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate CancerClinical Nuclear Medicine, 2018
- Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CTPharmaceuticals, 2017
- A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experienceWorld Journal of Nuclear Medicine, 2017
- 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate CancerEuropean Urology, 2016
- Prospective evaluation of 68Gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancerBJU International, 2016
- Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate CancerJournal of Urology, 2016
- See the unseen: Mesorectal lymph node metastases in prostate cancerThe Prostate, 2016